case_images: PMC10601826_01
case_images: Overview of diagnostic and therapeutic measures and outcomes over time. BSC, best supportive care; CT, chemotherapy; LMS, leiomyosarcoma; pall., palliative; PD, progressive disease; PR, partial remission; pul. Met., pulmonary metastasis; SD, stable disease; w, with.
case_images: cro-2023-0016-0001-533827_F01.jpg
case_images: PMC10601826_01_cro-2023-0016-0001-533827_F01.jpg
case_images: F1
case_images: Figure 1 shows a chronological overview of diagnostic and therapeutic measures and outcomes over time.
case_images: Abdominal CT images at diagnosis and during trabectedin treatment. a CT 10/21 at initial diagnosis. The arrow depicts the tumor with extensive contact with the vena cava. b Partial response in the reference pulmonary lesion (blue arrow) during trabectedin therapy. CT left: 01/22, CT right: 04/22.
case_images: cro-2023-0016-0001-533827_F02.jpg
case_images: PMC10601826_01_cro-2023-0016-0001-533827_F02.jpg
case_images: F2
case_images: In a CT conducted in October 2021 (Fig. 2a) at our center, the known pulmonary lesions were shown to have progressed in size (from 1 mm to approximately 5 mm), but new pulmonary lesions could not be clearly demarcated. After 4 cycles of trabectedin (April 2022), a CT of the trunk showed partial remission according to RECIST criteria (Fig. 2b).